Literature DB >> 12743279

CpG methylation of human papillomavirus type 16 DNA in cervical cancer cell lines and in clinical specimens: genomic hypomethylation correlates with carcinogenic progression.

Vinay Badal1, Linda S H Chuang, Eileen Hwee-Hong Tan, Sushma Badal, Luisa L Villa, Cosette M Wheeler, Benjamin F L Li, Hans-Ulrich Bernard.   

Abstract

Infection with genital human papillomaviruses (HPVs) is the primary cause of cervical cancer. The infection is widespread, and little is known about the secondary factors associated with progression from subclinical infection to invasive carcinoma. Here we report that HPV genomes are efficiently targeted in vivo by CpG methylation, a well-known mechanism of transcriptional repression. Indeed, it has been shown previously that in vitro-methylated HPV type 16 (HPV-16) DNA is transcriptionally repressed after transfection into cell cultures. By using a scan with the restriction enzyme McrBC, we observed a conserved profile of CpG hyper- and hypomethylation throughout the HPV-16 genomes of the tumor-derived cell lines SiHa and CaSki. Methylation is particularly high in genomic segments overlying the late genes, while the long control region (LCR) and the oncogenes are unmethylated in the single HPV-16 copy in SiHa cells. In 81 patients from two different cohorts, the LCR and the E6 gene of HPV-16 DNA were found to be hypermethylated in 52% of asymptomatic smears, 21.7% of precursor lesions, and 6.1% of invasive carcinomas. This suggests that neoplastic transformation may be suppressed by CpG methylation, while demethylation occurs as the cause of or concomitant with neoplastic progression. These prevalences of hyper- and hypomethylation also indicate that CpG methylation plays an important role in the papillomavirus life cycle, which takes place in asymptomatic infections and precursor lesions but not in carcinomas. Bisulfite modification revealed that in most of the HPV-16 genomes of CaSki cells and of asymptomatic patients, all 11 CpG dinucleotides that overlap with the enhancer and the promoter were methylated, while in SiHa cells and cervical lesions, the same 11 or a subset of CpGs remained unmethylated. Our report introduces papillomaviruses as models to study the mechanism of CpG methylation, opens research on the importance of this mechanism during the viral life cycle, and provides a marker relevant for the etiology and diagnosis of cervical cancer.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12743279      PMCID: PMC154984          DOI: 10.1128/jvi.77.11.6227-6234.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  48 in total

1.  CpG methylation directly inhibits binding of the human papillomavirus type 16 E2 protein to specific DNA sequences.

Authors:  A Thain; O Jenkins; A R Clarke; K Gaston
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

2.  CCAAT displacement protein, a regulator of differentiation-specific gene expression, binds a negative regulatory element within the 5' end of the human papillomavirus type 6 long control region.

Authors:  S Pattison; D G Skalnik; A Roman
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

3.  Characterization of late gene transcripts expressed during vegetative replication of human papillomavirus type 31b.

Authors:  M A Ozbun; C Meyers
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

4.  Extension of chromatin accessibility by nuclear matrix attachment regions.

Authors:  T Jenuwein; W C Forrester; L A Fernández-Herrero; G Laible; M Dull; R Grosschedl
Journal:  Nature       Date:  1997-01-16       Impact factor: 49.962

5.  Nuclear matrix attachment regions of human papillomavirus type 16 repress or activate the E6 promoter, depending on the physical state of the viral DNA.

Authors:  W Stünkel; Z Huang; S H Tan; M J O'Connor; H U Bernard
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

Review 6.  Papillomavirus infections--a major cause of human cancers.

Authors:  H zur Hausen
Journal:  Biochim Biophys Acta       Date:  1996-10-09

7.  Nuclear matrix attachment regions antagonize methylation-dependent repression of long-range enhancer-promoter interactions.

Authors:  W C Forrester; L A Fernández; R Grosschedl
Journal:  Genes Dev       Date:  1999-11-15       Impact factor: 11.361

Review 8.  Cytosine methylation and the ecology of intragenomic parasites.

Authors:  J A Yoder; C P Walsh; T H Bestor
Journal:  Trends Genet       Date:  1997-08       Impact factor: 11.639

9.  Genomic cloning and characterization of the nonoccupied allele corresponding to the integration site of human papillomavirus type 16 DNA in the cervical cancer cell line SiHa.

Authors:  R Bauer-Hofmann; C Borghouts; E Auvinen; E Bourda; F Rösl; A Alonso
Journal:  Virology       Date:  1996-03-01       Impact factor: 3.616

Review 10.  The epidemiology of cervical carcinogenesis.

Authors:  M H Schiffman; L A Brinton
Journal:  Cancer       Date:  1995-11-15       Impact factor: 6.860

View more
  71 in total

1.  Patterns of cellular and HPV 16 methylation as biomarkers for cervical neoplasia.

Authors:  Divya A Patel; Laura S Rozek; Justin A Colacino; Adrienne Van Zomeren-Dohm; Mack T Ruffin; Elizabeth R Unger; Dana C Dolinoy; David C Swan; Juanita Onyekwuluje; Cecilia R DeGraffinreid; Electra D Paskett
Journal:  J Virol Methods       Date:  2012-06-01       Impact factor: 2.014

Review 2.  Papillomavirus genome structure, expression, and post-transcriptional regulation.

Authors:  Zhi-Ming Zheng; Carl C Baker
Journal:  Front Biosci       Date:  2006-09-01

3.  High-throughput detection of human papillomavirus-18 L1 gene methylation, a candidate biomarker for the progression of cervical neoplasia.

Authors:  Tolga Turan; Mina Kalantari; Kate Cuschieri; Heather A Cubie; Hanne Skomedal; Hans-Ulrich Bernard
Journal:  Virology       Date:  2006-12-18       Impact factor: 3.616

4.  Methylation of human papillomavirus type 16 genome and risk of cervical precancer in a Costa Rican population.

Authors:  Lisa Mirabello; Chang Sun; Arpita Ghosh; Ana C Rodriguez; Mark Schiffman; Nicolas Wentzensen; Allan Hildesheim; Rolando Herrero; Sholom Wacholder; Attila Lorincz; Robert D Burk
Journal:  J Natl Cancer Inst       Date:  2012-03-23       Impact factor: 13.506

5.  In vitro progression of human papillomavirus 16 episome-associated cervical neoplasia displays fundamental similarities to integrant-associated carcinogenesis.

Authors:  Elizabeth Gray; Mark R Pett; Dawn Ward; David M Winder; Margaret A Stanley; Ian Roberts; Cinzia G Scarpini; Nicholas Coleman
Journal:  Cancer Res       Date:  2010-05-04       Impact factor: 12.701

Review 6.  Human papillomavirus-16 E5 protein: oncogenic role and therapeutic value.

Authors:  Niladri Ganguly
Journal:  Cell Oncol (Dordr)       Date:  2012-01-20       Impact factor: 6.730

7.  Folate and vitamin B12 may play a critical role in lowering the HPV 16 methylation-associated risk of developing higher grades of CIN.

Authors:  Chandrika J Piyathilake; Maurizio Macaluso; Michelle M Chambers; Suguna Badiga; Nuzhat R Siddiqui; Walter C Bell; Jeffrey C Edberg; Edward E Partridge; Ronald D Alvarez; Gary L Johanning
Journal:  Cancer Prev Res (Phila)       Date:  2014-08-21

Review 8.  Human papillomavirus DNA methylation as a potential biomarker for cervical cancer.

Authors:  Megan A Clarke; Nicolas Wentzensen; Lisa Mirabello; Arpita Ghosh; Sholom Wacholder; Ariana Harari; Attila Lorincz; Mark Schiffman; Robert D Burk
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-10-03       Impact factor: 4.254

9.  Elevated methylation of HPV16 DNA is associated with the development of high grade cervical intraepithelial neoplasia.

Authors:  Lisa Mirabello; Mark Schiffman; Arpita Ghosh; Ana C Rodriguez; Natasa Vasiljevic; Nicolas Wentzensen; Rolando Herrero; Allan Hildesheim; Sholom Wacholder; Dorota Scibior-Bentkowska; Robert D Burk; Attila T Lorincz
Journal:  Int J Cancer       Date:  2012-08-20       Impact factor: 7.396

10.  Distinct human papillomavirus type 16 methylomes in cervical cells at different stages of premalignancy.

Authors:  Janet L Brandsma; Ying Sun; Paul M Lizardi; David P Tuck; Daniel Zelterman; G Kenneth Haines; Maritza Martel; Malini Harigopal; Kevin Schofield; Matthew Neapolitano
Journal:  Virology       Date:  2009-05-13       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.